Christopher Hite
CIK: 0001814238
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (20 total)
- Sep 22, 2026RPRX
Royalty Pharma plc
Sale(S)Indirect3.9K shares at avg. $58.93$231K - Sep 22, 2026RPRX
Royalty Pharma plc
Sale(S)Indirect96.1K shares at avg. $58.51$5.6M - Aug 19, 2026RPRX
Royalty Pharma plc
Gift(G)Direct16.8K shares- - Aug 18, 2026RPRX
Royalty Pharma plc
Sale(S)Indirect100K shares at avg. $59.97$6.0M - Aug 5, 2026RPRX
Royalty Pharma plc
Award(A)Indirect11K shares- - Jun 30, 2026RPRX
Royalty Pharma plc
Sale(S)Indirect97.4K shares at avg. $56.50$5.5M - Jun 30, 2026RPRX
Royalty Pharma plc
Sale(S)Indirect2.6K shares at avg. $57.10$146K - Jun 30, 2026RPRX
Royalty Pharma plc
Sale(S)Direct29.4K shares at avg. $56.44$1.7M - Jun 30, 2026RPRX
Royalty Pharma plc
Sale(S)Direct600 shares at avg. $57.09$34K - Jun 23, 2026RPRX
Royalty Pharma plc
Sale(S)Indirect32.4K shares at avg. $54.11$1.8M - Jun 23, 2026RPRX
Royalty Pharma plc
Sale(S)Indirect117.6K shares at avg. $54.47$6.4M - May 6, 2026RPRX
Royalty Pharma plc
Award(A)Indirect24.3K shares- - Apr 16, 2026KLRA
Kailera Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
38.3K shares- - Mar 5, 2026VERA
Vera Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
24.9K shares- - Feb 11, 2026RPRX
Royalty Pharma plc
Award(A)Indirect26.6K shares- - Nov 5, 2025RPRX
Royalty Pharma plc
Award(A)Indirect6.2K shares- - Aug 6, 2025RPRX
Royalty Pharma plc
Award(A)Indirect3.7K shares- - May 16, 2025RPRX
Royalty Pharma plc
Award(A)IndirectClass E Ordinary Shares
1.2M shares- - May 8, 2025RPRX
Royalty Pharma plc
Award(A)Indirect48.6K shares- - Feb 14, 2025RPRX
Royalty Pharma plc
Conversion(C)Indirect300K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 22, 2026 |  RPRX Royalty Pharma plc | Sale(S) | 3,927 | $58.93 | $231,403 | Indirect |
| Sep 22, 2026 | RPRX Royalty Pharma plc | Sale(S) | 96,073 | $58.51 | $5,621,692 | Indirect |
| Aug 19, 2026 | RPRX Royalty Pharma plc | Gift(G) | 16,800 | - | $0 | Direct |
| Aug 18, 2026 | RPRX Royalty Pharma plc | Sale(S) | 100,000 | $59.97 | $5,997,250 | Indirect |
| Aug 5, 2026 | RPRX Royalty Pharma plc | Award(A) | 11,002 | - | $0 | Indirect |
| Jun 30, 2026 | RPRX Royalty Pharma plc | Sale(S) | 97,446 | $56.50 | $5,505,972 | Indirect |
| Jun 30, 2026 | RPRX Royalty Pharma plc | Sale(S) | 2,554 | $57.10 | $145,841 | Indirect |
| Jun 30, 2026 | RPRX Royalty Pharma plc | Sale(S) | 29,400 | $56.44 | $1,659,404 | Direct |
| Jun 30, 2026 | RPRX Royalty Pharma plc | Sale(S) | 600 | $57.09 | $34,254 | Direct |
| Jun 23, 2026 | RPRX Royalty Pharma plc | Sale(S) | 32,408 | $54.11 | $1,753,500 | Indirect |
| Jun 23, 2026 | RPRX Royalty Pharma plc | Sale(S) | 117,592 | $54.47 | $6,405,777 | Indirect |
| May 6, 2026 | RPRX Royalty Pharma plc | Award(A) | 24,263 | - | $0 | Indirect |
| Apr 16, 2026 |  KLRA Kailera Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 38,300 | - | - | Direct |
| Mar 5, 2026 |  VERA Vera Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 24,937 | - | - | Direct |
| Feb 11, 2026 | RPRX Royalty Pharma plc | Award(A) | 26,626 | - | $0 | Indirect |
| Nov 5, 2025 | RPRX Royalty Pharma plc | Award(A) | 6,168 | - | - | Indirect |
| Aug 6, 2025 | RPRX Royalty Pharma plc | Award(A) | 3,696 | - | - | Indirect |
| May 16, 2025 | RPRX Royalty Pharma plc | Award(A) Class E Ordinary Shares | 1,238,789 | - | - | Indirect |
| May 8, 2025 | RPRX Royalty Pharma plc | Award(A) | 48,646 | - | - | Indirect |
| Feb 14, 2025 | RPRX Royalty Pharma plc | Conversion(C) | 300,000 | - | - | Indirect |
1-20 of 20 transactions
About Hite Christopher
Hite Christopher (SEC CIK 0001814238) files insider reports with the SEC as EVP & Chairman, Partnering of Royalty Pharma plc (RPRX), Director of Kailera Therapeutics, Inc. (KLRA) and Director of Vera Therapeutics, Inc. (VERA).
Signal8 holds 16 ownership filings by Hite Christopher (2 Form 3, 14 Form 4), filed between Feb 18, 2025 and Sep 24, 2026. Those filings report 20 transactions, from Feb 14, 2025 to Sep 22, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Hite Christopher's filings is in NEW YORK, NY.
Recent filings by Hite Christopher
- Sep 22, 2026: Open-market sales of RPRX shares (2 lines, Form 4, code S).
- Aug 19, 2026: Gift of RPRX shares (Form 4, code G).
- Aug 18, 2026: Open-market sale of RPRX shares (Form 4, code S).
- Aug 5, 2026: Grant or award of RPRX shares (Form 4, code A).
- Jun 30, 2026: Open-market sales of RPRX shares (4 lines, Form 4, code S).
Other insiders filing for Royalty Pharma plc (RPRX)
- Urist Marshall, EVP, Research & Investments
- Bassler Bonnie L, Director
- Coyne Terrance P., EVP & CFO
- Legorreta Pablo G., CEO, Chairman of the Board
- WEATHERMAN ELIZABETH H, Director
- Norden Gregory, Director